|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang
X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kubelt C, Hattermann K, Sebens S, Mehdorn
HM and Held-Feindt J: Epithelial-to-mesenchymal transition in
paired human primary and recurrent glioblastomas. Int J Oncol.
46:2515–2525. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mikheeva SA, Mikheev AM, Petit A, Beyer R,
Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H,
González-Herrero I, et al: TWIST1 promotes invasion through
mesenchymal change in human glioblastoma. Mol Cancer. 9:1942010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kahlert UD, Maciaczyk D, Doostkam S, Orr
BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J,
Niedermann G, et al: Activation of canonical WNT/β-catenin
signaling enhances in vitro motility of glioblastoma cells by
activation of ZEB1 and other activators of
epithelial-to-mesenchymal transition. Cancer Lett. 325:42–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng WY, Kandel JJ, Yamashiro DJ, Canoll
P and Anastassiou D: A multi-cancer mesenchymal transition gene
expression signature is associated with prolonged time to
recurrence in glioblastoma. PLoS One. 7:e347052012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu W, Tian Y, Wan H, Ma J, Song Y, Wang Y
and Zhang L: Expression of β-catenin and E- and N-cadherin in human
brainstem gliomas and clinicopathological correlations. Int J
Neurosci. 123:318–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Camand E, Peglion F, Osmani N, Sanson M
and Etienne-Manneville S: N-cadherin expression level modulates
integrin-mediated polarity and strongly impacts on the speed and
directionality of glial cell migration. J Cell Sci. 125:844–857.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ostrom QT, Gittleman H, Liao P, Rouse C,
Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16
Suppl 4:iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park CK, Kim JE, Kim JY, Song SW, Kim JW,
Choi SH, Kim TM, Lee SH, Kim IH and Park SH: The changes in MGMT
promoter methylation status in initial and recurrent glioblastomas.
Transl Oncol. 5:393–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shchors K, Persson AI, Rostker F, Tihan T,
Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA and
Evan GI: Using a preclinical mouse model of high-grade astrocytoma
to optimize p53 restoration therapy. Proc Natl Acad Sci USA.
110:E1480–E1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka M, Koul D, Davies MA, Liebert M,
Steck PA and Grossman HB: MMAC1/PTEN inhibits cell growth and
induces chemosensitivity to doxorubicin in human bladder cancer
cells. Oncogene. 19:5406–5412. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wick W, Weller M, van den Bent M, Sanson
M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M and
Reifenberger G: MGMT testing-the challenges for biomarker-based
glioma treatment. Nat Rev Neurol. 10:372–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin L, Wang G, Ming J, Meng X, Han B, Sun
B, Cai J and Jiang C: Analysis of expression and prognostic
significance of vimentin and the response to temozolomide in glioma
patients. Tumour Biol. 37:15333–15339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatta K, Okada TS and Takeichi M: A
monoclonal antibody disrupting calcium-dependent cell-cell adhesion
of brain tissues: Possible role of its target antigen in animal
pattern formation. Proc Natl Acad Sci USA. 82:2789–2793. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Narita Y, Nagane M, Mishima K, Huang HJ,
Furnari FB and Cavenee WK: Mutant epidermal growth factor receptor
signaling down-regulates p27 through activation of the
phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer
Res. 62:6764–6769. 2002.PubMed/NCBI
|
|
24
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1:a0031292009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lammens T, Swerts K, Derycke L, De Craemer
A, De Brouwer S, De Preter K, Van Roy N, Vandesompele J, Speleman
F, Philippé J, et al: N-cadherin in neuroblastoma disease:
Expression and clinical significance. PLoS One. 7:e312062012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beasley GM, Riboh JC, Augustine CK, Zager
JS, Hochwald SN, Grobmyer SR, Peterson B, Royal R, Ross MI and
Tyler DS: Prospective multicenter phase II trial of systemic ADH-1
in combination with melphalan via isolated limb infusion in
patients with advanced extremity melanoma. J Clin Oncol.
29:1210–1215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Volk T and Geiger B: A 135-kd membrane
protein of intercellular adherens junctions. EMBO J. 3:2249–2260.
1984.PubMed/NCBI
|
